[Treatment of vertigo with betahistine and its clinical and electrophysiological evaluation].
Betahistine was administered during 4 weeks to 31 patients with vertigo, divided into 3 groups depending on changes in neurological examination. 1 group--13 patients without abnormalities, 2 group--11 with ischemia vertebrobasilaris, 3 group--7 with lesion of VIII nerves. Significant improvement was obtained in 20 patients (65%), most evident in group 1 (in 11). BAEP examination revealed abnormalities in 12 cases before the treatment and recovery in 4 (33.3%) after 4 weeks of treatment. They were: longer latency of the 1 component (39%), and III and V components mainly in the group with baso-vertebral ischemia. It confirms the supposition that disturbances of microcirculation are responsible for the mechanism of vertigo in these cases.
Wasilewska
H
H
Kliniki Neurologicznej Centralnego, Szpitala Klinicznego WAM w Warszawie.
Domzał
T M
TM
D000328:Adult; D000368:Aged; D001621:Betahistine / Q000627:therapeutic use*; D007758:Ear, Inner / Q000098:blood supply; D016057:Evoked Potentials, Auditory, Brain Stem / Q000502:physiology*; D005260:Female; D017442:Histamine Agonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008833:Microcirculation / Q000502:physiology; D008875:Middle Aged; D014715:Vertebrobasilar Insufficiency / Q000150:complications; D014717:Vertigo / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology
D017442:Histamine Agonists; D001621:Betahistine
Zawroty głowy--leczenie betahistyna z ocena kliniczna i elektrofizjologiczna (słuchowe potencjały wywołane pnia mózgu).